在慢性淋巴细胞白血病中准B细胞受体信号通路
John T Patton1, Jennifer A Woyach1
1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
Seminars in hematology
|May 15, 2024
概括
异常的B细胞受体 (BCR) 信号驱动慢性淋巴细胞白血病 (CLL). 抑制剂的目标是布鲁顿.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 异常的B细胞受体 (BCR) 信号传递是慢性淋巴细胞白血病 (CLL) /小淋巴细胞淋巴瘤 (SLL) 病变发生的关键驱动因素.
- 依赖BCR的信号传递对于恶性B细胞的生长和存活至关重要,将下游通路定位为治疗点.
- 选择性抑制布鲁顿氨酸激酶 (BTK) 和氨酸 3-激酶 (PI3K) 的药物已在B细胞恶性瘤中显示出显著的疗效.
研究的目的:
- 审查BCR信号在CLL病变发生中的关键作用.
- 总结目前的CLL治疗环境,重点关注BCR相关的激酶抑制剂.
- 讨论新兴的治疗策略和正在进行的针对BCR相关激酶的临床试验.
主要方法:
- 对CLL中BCR信号通路的文献综述.
- 对BTK和PI3K抑制剂在CLL和其他B细胞淋巴瘤中的临床数据和结果的分析.
- 目前和研究中的治疗方法的概述,针对BCR相关激酶.
主要成果:
- BTK 抑制剂彻底改变了CLL的治疗方法,显示了长期的疗效和高响应率.
- 由于相关的毒性,PI3K抑制剂在CLL中使用较少.
- 结核性结核性淋巴瘤仍然无法治愈,这凸显了对新型治疗的需求,特别是在复发或对向疗法的耐药性发展后.
结论:
- 准BCR相关激酶是CLL的关键治疗策略.
- 虽然BTK抑制剂已经确立,但对优化PI3K抑制和探索新激酶标的进一步研究是有必要的.
- 解决CLL的治疗耐药性和复发需要继续对BCR信号通路及其抑制剂进行调查.
相关概念视频
01:24B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:31The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
01:15Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K